Charles Kunsch

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

NextRNA Therapeutics, Inc. is a Boston-based biotechnology company leading the next revolution of RNA-directed therapeutics. Our focus is on identifying and drugging long non-coding RNAs (lncRNAs) with small molecules in oncology and neuroscience. Our proprietary computational engine, combined with deep lncRNA biology expertise and strong drug discovery capabilities, positions us well to unlock the therapeutic value of lncRNAs, a vast and promising target space. NextRNA has assembled an experienced team of industry leaders, biology and chemistry experts, and drug developers, all driven by a common passion for working together and having an impact on science and patients.

Novel therapeutics for conformational blockade of RAS in cancer.

Based in Boston, Massachusetts and named after the Japanese deity that tamed fire for the good of humanity, Kojin is harnessing groundbreaking discoveries in cell-state and ferroptosis biology to develop first-in-class treatments for use in patients with cancer, and autoimmune and inflammatory diseases, among other disorders. Kojin has developed a drug-discovery platform that integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover therapeutics that specifically modulate ferroptosis, a recently discovered and characterized cell-death mechanism. The Kojin team brings together scientific leadership in chemical biology, genetics, immunology, cancer therapeutics, drug discovery, and clinical development, as well as broad experience in biotechnology entrepreneurship.

Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.

At Prevail Therapeutics, we are developing novel gene therapies that target the root genetic causes of Parkinson’s disease and other neurodegenerative disorders. Our mission is to translate recent advances in human genetics and gene therapy technology into medicines that slow or stop the neurodegenerative process. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders. Prevail was formed in 2017 and we are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City. Prevail Therapeutics was acquired by Eli Lilly and Company in January of 2021, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the www.lilly.com website.

Faze Medicines is a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates. Our entire team is excited by the opportunity to harness this transformative moment in cell biology and translate discoveries in the lab to make a difference for patients. We are explorers in an emerging field, approaching this work with rigor and passion and having fun together along the way. We hope you’ll join us to write the next chapter of cell biology.

The endoplasmic reticulum is a structure within cells that is responsible for multiple functions, including serving as a sensor of cellular stress. Persistent ER stress has a significant impact in a number of diseases including cancer and neurodegenerative disease, as well as autoimmune conditions. Quentis Therapeutics is translating novel biology into new therapeutic approaches to address ER stress in multiple diseases, beginning with our first program in cancer. The company’s first-in-class IRE1α inhibitor is designed to target ER stress pathways and awaken the immune system’s ability to fight cancer. Founded by a team with deep drug discovery and development experience, we are building a leading New York City-based biotechnology company driven by a commitment to scientific excellence and a passion to help patients.

Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Aquinnah Pharmaceuticals is focused on a new area of research and development to modulate neurodegenerative stress granules, believed to be important in the pathology of amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. The medical need for ALS is very high as there are currently no effective treatments for this devastating neurodegenerative disease. ALS progresses rapidly, eventually affecting muscles in the arms, legs, face, diaphragm, and chest. Today, approximately 60% of patients with ALS will not survive beyond three years following diagnosis, with 10% of new patients surviving at least 10 years. Aquinnah Pharmaceuticals has identified lead molecules advancing to clinical studies which are designed to prevent and potentially reverse the pathological stress granules in affected patients. In addition to their use in ALS, these compounds also show promise as a potential treatment for cognition impairment in patients with Alzheimer’s disease and other neurodegenerative diseases. New work published in Nature Neuroscience by co-founder Ben Wolozin, M.D.,Ph.D., has implicated stress granule disease progression with tau; which is a neuronal pathologic protein that correlates with Alzheimer's disease progression. Aquinnah is pioneering new approaches to identify small molecule drugs that modulate intracellular tau-stress granule biology, representing a new first in class treatment for Alzheimer's disease and other tauopathy diseases.

Medincell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives. #BetterMedicineForAll #ImpactHealth #GlobalHealth #ControlledRelease #CreativeThinking #InnovationForward #Science

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

Dreavent is a Boston-based biotech venture capital firm with a structured model to connect scientific ecosystems to Bostons biotech infrastructure, engineering assets against confirmed pharmaceutical interest. Our Bio Asset Engineering Platform combines a specialized Linking Team embedded in both the local ecosystem and Boston, a Boston Development Platform where assets are developed to global pharmaceutical standards, and the Dreavent Engine, a proprietary AI-powered investment intelligence system. Spain is the first implementation. The model is designed to scale globally, with Boston as the permanent hub. Dreavent. Connecting Ecosystems.

NextRNA Therapeutics, Inc. is a Boston-based biotechnology company leading the next revolution of RNA-directed therapeutics. Our focus is on identifying and drugging long non-coding RNAs (lncRNAs) with small molecules in oncology and neuroscience. Our proprietary computational engine, combined with deep lncRNA biology expertise and strong drug discovery capabilities, positions us well to unlock the therapeutic value of lncRNAs, a vast and promising target space. NextRNA has assembled an experienced team of industry leaders, biology and chemistry experts, and drug developers, all driven by a common passion for working together and having an impact on science and patients.

Novel therapeutics for conformational blockade of RAS in cancer.